Jinling Pharmaceutical (SHE:000919) agreed to postpone the ready-to-use date of the core active pharmaceutical ingredient and high-end pharmaceutical intermediates common production platform to 2028, according to a Wednesday filing on the Shenzhen bourse.

The platform was supposed to be scheduled to start in March this year but has to be moved to control the overall project quality and meet management requirements.

The pharmaceutical company's shares rose over 1% at the close.